title: Malignant bowel obstruction in advanced ovarian cancer.
abstract: OBJECTIVE
  Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.
  
  
  METHODS
  This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.
  
  
  RESULTS
  At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).
  
  
  CONCLUSIONS
  The Manchester Bowel Obstruction Score may aide treatment stratification.
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.|Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK.
authors.forename: Emma
authors.initials: E
authors.lastname: Dean
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.|AstraZeneca Ltd, Early Clinical Development, Melbourn Science Park, Melbourn, Hertfordshire, SG8 6HB, UK.
authors.forename: Leila
authors.initials: L
authors.lastname: Khoja
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.|Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Clamp
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.|Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK.
authors.forename: Gordon C
authors.initials: GC
authors.lastname: Jayson
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.|Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester, M13 9NT, UK.
authors.forename: Dilly
authors.initials: D
authors.lastname: Goonetilleke
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.
authors.forename: Alicia M
authors.initials: AM
authors.lastname: Conway
authors.affiliation: The Christie NHS Foundation Trust & Institute of Cancer Sciences, Manchester, M20 4BX, UK.
authors.forename: Jurjees
authors.initials: J
authors.lastname: Hasan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019468:Disease Management; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000175:diagnosis* / Q000209:etiology* / Q000601:surgery / Q000628:therapy; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome
keywords: Manchester Bowel Obstruction Score; bowel obstruction; ovarian cancer; prognostic score